Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer - Guideline Learning Activities - Guideline Central

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

American Society of Clinical OncologyCancer Care Ontario

Publication Date: January 18, 2022

The Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer guideline, developed by the American Society of Clinical Oncology and Cancer Care Ontario, provides evidence-based recommendations for the use of adjuvant bone-modifying agents in breast cancer.
4
Questions
11
Minutes Est.
80
Possible Points
Unrated
Difficulty
Objectives
  • Recognizing eligibility for adjuvant bisphosphonate therapy in breast cancer
  • Understanding optimal timing to start bisphosphonate therapy in breast cancer
  • Identifying bisphosphonates with the most robust evidence as adjuvant therapy in breast cancer
Instructions
Answer All QuestionsYou must answer each question to move forward.
Get Instant FeedbackAfter you submit each answer, you'll receive an explanation.
Progress is Saved AutomaticallyYour progress is saved as you go, so you can stop and return to the quiz anytime.
Compare Your ResultsSee how your performance compares with your peers after each answer is submitted.
Earn PointsPoints are awarded for each correct answer.
Members Only FeaturesIf you're a member, you can track your progress and view the quizzes you've completed.
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.